Solventum Corp (SOLV)

Solventum Corporation is a global healthcare company that develops, manufactures, and commercializes a broad portfolio of solutions built on material science, data science, and digital capabilities. It has more than 70 years of history in discovering and developing advanced solutions. Its products and services are used along a patient's journey through prevention, diagnosis, treatment, and recovery. In 2025 the company acquired Acera Surgical, a privately held bioscience company, and sold its Purification and Filtration business to Thermo Fisher Scientific.

The company reports three segments. MedSurg (57.9% of 2025 sales) offers negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies OEM offerings. Dental Solutions (16.2%) provides dental and orthodontic products such as brackets, aligners, restorative cements, and bonding agents. Health Information Systems (16.3%) supplies software for computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization, aimed at reducing revenue cycle waste and clinician administrative burden. Research and development employs about 2,000 people, organized within each segment and across segments.

Solventum serves customers ranging from multidisciplinary hospitals to local clinics and practices, with sales in over 90 countries. Its products are purchased mainly by hospitals, physicians, and other providers that bill government programs and private payers, so cost containment and reimbursement policies in markets such as the U.S. and China affect it. It sells through direct, distributor, key account, inside sales, and e-commerce channels, supported by clinical specialists, medical liaisons, and application engineers. In emerging regions of Latin America, Europe, the Middle East and Africa, and Asia, it uses an export model with local partners.

The company manages sourcing, production, and distribution globally through a hub-and-spoke distribution network. It has a supply chain resiliency program with regional supply sources, dual-source manufacturing, and vertically integrated operations. While separating from 3M, it still relies on 3M's distribution networks and manufacturing sites under a Transition and Distribution Agreement and a Transition Contract Manufacturing Agreement. It has about 20,000 employees, including roughly 10,000 in the United States, 2,000 in Germany, and 4,000 production employees. Competitors include Smith & Nephew, Mölnlycke, Coloplast, and Convatec in wound care; Becton Dickinson, Medline, Cardinal Health, and Steris in infection prevention and surgical supplies; Dentsply Sirona, Envista, Straumann, Ivoclar, and Align Technology in dental; and Optum, Microsoft (Nuance), Epic, Oracle (Cerner), Waystar, and Athena in health information technology. It is subject to extensive healthcare, environmental, health and safety, and product regulation, and relies on patents, trademarks, and trade secrets to protect its technology.